Colette van Buchem
Good afternoon, and welcome, everyone. I’m Colette van Buchem, an associate at JPMorgan on the health care team in New York. Today, it’s my pleasure to introduce Anavex Life Sciences. With me on stage, we have Christopher Missling, President and CEO. Christopher, I’ll pass it over to you. Thank you.
Christopher Missling
President, CEO, Secretary & Director
I appreciate the very kind introduction and an invitation to the JPMorgan conference. Let me introduce Anavex Life Sciences. Since we are a public company, I’d like you to read this.
I learned from a successful oncology research, which I was involved before prior to Anavex that one important lesson. The power of the body to fight cancer by activating the body on defense mechanism. That led to the question, why wouldn’t that be possible with CNS diseases, which consist of even more complex pathologies. Here at Anavex, we like to change things. We like to move science forward. We are dedicated to therapeutics, discovery and development of targeted central nervous systems treatment.
Instead of trying to fix already broken things happening downstream within the neuron, we try to fix wrong things at the start, at the upstream, at the reaction cascade or processes. The way to address complex diseases especially in Alzheimer’s disease, is transforming brain health to patient-oriented personalized medicine. And the company’s lead asset, blarcamesine is a once-daily oral small molecule that enhances our autophagy through sigma-1 activation and restore cellular homeostasis.
Impaired autophagy processes are upstream of both a beta and tau and therefore anticipate the neurodegenerative process in Alzheimer’s
